Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-24
2007-04-24
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S568000, C514S428000
Reexamination Certificate
active
11543622
ABSTRACT:
This invention provides compounds of formula I:wherein a, b, c, e, m, R1, R2, R3, R4a, R4b, R5, R6, R7, and R8are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
REFERENCES:
patent: 3192221 (1965-06-01), Lunsford et al.
patent: 3247222 (1966-04-01), Lunsford
patent: 3732247 (1973-05-01), Helsley et al.
patent: 3984557 (1976-10-01), Welstead, Jr.
patent: 4002766 (1977-01-01), Welstead, Jr.
patent: 4594343 (1986-06-01), Shanklin, Jr.
patent: 4810713 (1989-03-01), Yanni et al.
patent: 4950674 (1990-08-01), Yanni et al.
patent: 5070087 (1991-12-01), Teng et al.
patent: 5096890 (1992-03-01), Cross et al.
patent: 5340831 (1994-08-01), Cross et al.
patent: 5344835 (1994-09-01), Alker et al.
patent: 5486527 (1996-01-01), Alker et al.
patent: 5607950 (1997-03-01), Alker et al.
patent: 5750540 (1998-05-01), Tsuchiya et al.
patent: 5932594 (1999-08-01), Cross et al.
patent: 6130232 (2000-10-01), Mase et al.
patent: 6433027 (2002-08-01), Bozung et al.
patent: 6693202 (2004-02-01), Aggen et al.
patent: 2003/0018019 (2003-01-01), Meade et al.
patent: 2004/0122014 (2004-06-01), Mammen et al.
patent: 2004/0254219 (2004-12-01), Mammen et al.
patent: 2005/0026954 (2005-02-01), Mammen et al.
patent: 2005/0113413 (2005-05-01), Wilson et al.
patent: 2005/0203167 (2005-09-01), Mammen et al.
patent: 0 178 946 (1986-04-01), None
patent: 0 235 463 (1987-09-01), None
patent: 0 999 205 (2000-05-01), None
patent: 1 020 449 (2000-07-01), None
patent: 11 100366 (1999-04-01), None
patent: WO 95/06635 (1995-03-01), None
patent: WO 98/54167 (1998-12-01), None
patent: WO 2004/089892 (2004-10-01), None
patent: WO 2004/089892 (2004-10-01), None
patent: WO 2005/042514 (2005-05-01), None
U.S. Appl. No. 10/813,745, Mammen et al.
Broadley et al., “Muscarinic Receptor Agonists and Antagonists”, Molecules, 6, pp. 142-193 (2001).
Cale et al., “A Series of Central Nervous System Stimulants Based on the 4-Substituted 3,3-Diphenyl-2-pyrrolidinone Skeleton. II”, J. Med. Chem., 10(2), pp. 214-222 (1967).
Eglen et al., “Muscarinic Receptor Subtypes:Pharmacology and Therapeutic Potential”, DN&P, 10(8), pp. 462-469 (1997).
Graul et al., “Darifenacin”, Drugs of the Future, 21(11), pp. 1105-1108 (1996).
Taniguchi et al., “Agents for the Treatment of Overactive Detrusor, VI.1a)Synthesis and Pharmacological Properties of Acetamide Derivatives Bearing Cyclic Amines inN-Substitutents”, Chem. Pharm. Bull, 42(1), pp. 74-84) 1994.
Zlotos et al., “Muscarinic receptor agonists and antagonists”, Exp. Opin. Ther. Patents, 9(8), pp. 1029-1053 (1999).
Dunham Sarah
Ji Yu-Hua
Li Li
Mammen Mathai
Eberle Shelley
Hagenah Jeffrey A.
Saeed Kamal A.
Theravance Inc.
LandOfFree
Diphenylmethyl compounds useful as muscarinic receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diphenylmethyl compounds useful as muscarinic receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diphenylmethyl compounds useful as muscarinic receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3752578